Space News from SpaceDaily.com
From Covid to cancer: High hopes for 'versatile' mRNA
ADVERTISEMENT

Paris, Oct 15 (AFP) Oct 15, 2021
The coronavirus pandemic has made vaccines from Pfizer/BioNTech and Moderna and the mRNA technology that they use into household names.

These types of jabs are new but researchers have been working for decades to try to figure out how to use messenger RNA for other vaccinations and to treat illnesses from AIDS to cancer.


- How does it work? -


Messenger RNA's job in the body is to help deliver specific instructions from DNA to cells.

In the case of the Pfizer/BioNTech and Moderna jabs, lab-generated mRNA tells human cells to create antigens -- proteins that are similar to ones found in the Covid-19 virus.

Thanks to those antigens, a person's immune system learns how to fight the virus and neutralise Covid if it enters the body.

After the cells create these proteins, the body breaks down the mRNA instructions and gets rid of them.

Such direct communication with cells is revolutionary -- classic vaccines aimed to provoke an immune response by injecting a neutralised form of a virus or antigens into the system.


- Where did this come from? -


The first big breakthrough, in the late 1970s, was in using mRNA to make test-tube cells produce proteins.

A decade later, scientists were able to get the same results in mice, but mRNA still had two major drawbacks as a medical tool.

For one thing, cells in live animals resisted synthetic mRNA, provoking a dangerous immune response.

On top of that, mRNA molecules are fragile, making them difficult to deliver to the system without altering them.

In 2005 researchers Katalin Kariko and Drew Weissman of Penn State University published a groundbreaking study showing that a lipid -- or fat molecule -- envelope could safely deliver mRNA without negative effects.

The research caused a buzz in the pharmaceutical community and start-ups dedicated to mRNA therapies began to pop up around the world.


- What else can mRNA do? -


Scientists have worked on developing mRNA jabs for illnesses like seasonal flu, rabies and Zika, as well as those that have remained vaccine-resistant until now, including malaria and AIDS.

Researchers have also started testing personalised treatments on cancer patients, using samples of the proteins in their tumours to create specialised mRNA.

This then triggers the immune system to target specific cancer cells.

"The mRNA platform is versatile," University of Pennsylvania biochemist Norbert Pardi told AFP, "any protein can be encoded as mRNA so there are many potential applications."

jdy-nrh/mh/klm/jxb

PFIZER

BioNTech


ADVERTISEMENT




Space News from SpaceDaily.com
Technical setback delays launch of final Delta IV Heavy
Japan Moon probe survives second lunar night
Europe space telescope's sight restored after de-icing procedure

24/7 Energy News Coverage
Revolutionizing Particle Physics: AI's Role in Deciphering Complex Particle Paths
UC San Diego Scientists Unveil Plant-Based Polymers that Biodegrade Microplastics in Months
Cambridge working to unlock new solar energy pathways

Military Space News, Nuclear Weapons, Missile Defense
AI generates high-quality images 30 times faster in a single step
Aerospacelab and Xona Unite to Transform Satellite Navigation
GITAI's robotic system triumphs in ISS demo

24/7 News Coverage
'Just staggering': UN says households waste 1 bn meals a day
Neolithic Mariners: Unveiling the Mediterranean's Oldest Boats
Greece to buy seven Canadian water bombers for wildfires


All rights reserved. Copyright Agence France-Presse. Sections of the information displayed on this page (dispatches, photographs, logos) are protected by intellectual property rights owned by Agence France-Presse. As a consequence, you may not copy, reproduce, modify, transmit, publish, display or in any way commercially exploit any of the content of this section without the prior written consent of Agence France-Presse.